Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTP-01 in Advanced Solid Tumors
NCT07266428Phase 2Recruiting
- Sponsor
- Ottimo Pharma
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of OTP-01 in solid tumor, sponsored by Ottimo Pharma. Started Dec 2025; status: recruiting.
02
Drugs
OTP-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07266428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266428.